We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF
IDNA

67 hedge funds and large institutions have $47.9M invested in iShares Genomics Immunology and Healthcare ETF in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

4% more capital invested

Capital invested by funds: $46.1M → $47.9M (+$1.78M)

0.88% more ownership

Funds ownership: 32.69% → 33.57% (+0.88%)

11% less funds holding

Funds holding: 75 → 67 (-8)

73% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 11

Holders
67
Holders Change
-8
Holders Change %
-10.67%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
22
Reduced
19
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IWC
Integrated Wealth Concepts
Massachusetts
+$1.34M
2
Bank of America
Bank of America
North Carolina
+$836K
3
Morgan Stanley
Morgan Stanley
New York
+$806K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$603K
5
PCA
Pallas Capital Advisors
Massachusetts
+$428K

Top Sellers

Rank Fund Capital Flow
1
WBG
Wharton Business Group
Pennsylvania
-$1.06M
2
WAP
Wealthcare Advisory Partners
Pennsylvania
-$990K
3
SFFS
Stonehage Fleming Financial Services
Jersey
-$465K
4
LPL Financial
LPL Financial
California
-$392K
5
AWM
Apollon Wealth Management
South Carolina
-$371K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCA
26
Pallas Capital Advisors
Massachusetts
$428K +$428K +17,841 New
SM
27
Sweeney & Michel
California
$411K -$125K -5,212 -22%
WGCA
28
Wolf Group Capital Advisors
Virginia
$351K – – –
LWM
29
Lodestone Wealth Management
Washington
$336K +$306K +12,753 New
CPRC
30
Consolidated Portfolio Review Corp
New York
$312K -$45.5K -1,896 -12%
Goldman Sachs
31
Goldman Sachs
New York
$274K – – –
NSAM
32
North Star Asset Management
Wisconsin
$259K – – –
Wells Fargo
33
Wells Fargo
California
$251K +$11K +457 +4%
BTWM
34
Baker Tilly Wealth Management
Wisconsin
$249K -$35.4K -1,477 -12%
CA
35
Cetera Advisors
Colorado
$243K +$72 +3 +0%
KAS
36
Kestra Advisory Services
Texas
$215K -$296K -12,354 -57%
WCM
37
Wealthcare Capital Management
Virginia
$210K -$4.7K -196 -2%
IA
38
IFP Advisors
Florida
$111K -$792 -33 -0.7%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$63.9K -$17K -710 -21%
BFEC
40
Benjamin F. Edwards & Company
Missouri
$42K +$5.61K +234 +15%
CSPIA
41
Cary Street Partners Investment Advisory
Virginia
$37.4K – – –
S
42
SignatureFD
Georgia
$35K – – –
BFPW
43
BOK Financial Private Wealth
Colorado
$31.1K – – –
SS
44
Sunbelt Securities
Texas
$26.6K – – –
VWM
45
Venturi Wealth Management
Texas
$24.3K -$26.3K -1,096 -51%
AIC
46
Archer Investment Corporation
Indiana
$23.4K – – –
PCFFS
47
Pacific Center for Financial Services
California
$19.7K +$72 +3 +0.4%
RCM
48
Raleigh Capital Management
North Carolina
$19.1K +$48 +2 +0.2%
BC
49
Barrett & Company
Rhode Island
$17.5K – – –
PNC Financial Services Group
50
PNC Financial Services Group
Pennsylvania
$16.4K – – –
1
2
3 4

IDNA Hedge Fund Activity: Q2 2023 in Review

67 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2023, worth a combined $47.9M — up 3.9% from $46.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of IDNA and 3 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 22 added.

The largest buyer was Integrated Wealth Concepts, adding an estimated $1.34M. The largest seller was Wharton Business Group, cutting an estimated $1.06M.

  • 67 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2023, down from 75 in Q1 2023.
  • Funds reported $47.9M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2023, up 3.9% quarter-over-quarter.
  • 3 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2023 and 11 closed out, a net change of -8 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2023 was Integrated Wealth Concepts, an estimated $1.34M added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q2 2023 was Wharton Business Group, an estimated $1.06M sold.

Based on aggregated 13F filings for Q2 2023.